PT - JOURNAL ARTICLE AU - Sherman Picardo AU - Kenji So AU - Kannan Venugopal AU - Marcus Chin TI - Vedolizumab-induced acute pancreatitis: the first reported clinical case AID - 10.1136/bcr-2017-222554 DP - 2018 Jan 05 TA - BMJ Case Reports PG - bcr-2017-222554 VI - 2018 4099 - http://casereports.bmj.com/content/2018/bcr-2017-222554.short 4100 - http://casereports.bmj.com/content/2018/bcr-2017-222554.full AB - Drug-induced acute pancreatitis (DIAP) is a rare, but clinically significant diagnosis. Vedolizumab, an α4β7 integrin inhibitor, which was approved in 2015 for treatment of moderate to severe inflammatory bowel disease, is a well-tolerated medication with a favourable safety profile and minimal serious adverse events in premarketing clinical trials. We present the first reported case of acute pancreatitis directly attributable to vedolizumab.